Abstract
Usually, wherever breast STAT5a is present, PRLR is reduced; without STAT5a PRLR becomes abundant. Five breast lesions essentially lacking both were tested immunohistochemically for PRLR isoforms. The intermediate isoform was essentially only detected in these lesions. In some breast lesions PRLR isoforms may be involved in JAK/STAT pathway disturbances.
Keywords: Breast, STAT5a, PRLR, Immunohistochemistry, Intermediate Isoform
Protein & Peptide Letters
Title: Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease
Volume: 17 Issue: 1
Author(s): G. L. Bratthauer, M. D. Stamatakos and T. N. Vinh
Affiliation:
Keywords: Breast, STAT5a, PRLR, Immunohistochemistry, Intermediate Isoform
Abstract: Usually, wherever breast STAT5a is present, PRLR is reduced; without STAT5a PRLR becomes abundant. Five breast lesions essentially lacking both were tested immunohistochemically for PRLR isoforms. The intermediate isoform was essentially only detected in these lesions. In some breast lesions PRLR isoforms may be involved in JAK/STAT pathway disturbances.
Export Options
About this article
Cite this article as:
Bratthauer L. G., Stamatakos D. M. and Vinh N. T., Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease, Protein & Peptide Letters 2010; 17(1) . https://dx.doi.org/10.2174/092986610789909467
DOI https://dx.doi.org/10.2174/092986610789909467 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Drugs Interfering with Apoptosis in Breast Cancer
Current Pharmaceutical Design Editorial (Thematic Issue: Emerging Azoles: Structure Function Relationship and Their Therapeutic Potential)
The Natural Products Journal ABC Transporters in the CNS – An Inventory
Current Pharmaceutical Biotechnology Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry Anti-Inflammatory Therapy for Alzheimer’s Disease from Epidemiological Fact to New Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Modification of Decoy Oligodeoxynucleotides to Achieve the Stability and Therapeutic Efficacy
Current Topics in Medicinal Chemistry Cancer Diagnosis and Disease Gene Identification <i>via</i> Statistical Machine Learning
Current Bioinformatics Epigenetic Biomarkers for Risk Assessment of Particulate Matter Associated Lung Cancer
Current Drug Targets New Poly(3-hydroxybutyrate) Microparticles with Paclitaxel Sustained Release for Intraperitoneal Administration
Anti-Cancer Agents in Medicinal Chemistry Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets Gold and Silver Nanoparticles in Bioassay, Cell Visualization and Therapy
Current Clinical Pharmacology Nanostructured Systems for the Organelle-specific Delivery of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Metal Complexes of Uracil Derivatives with Cytotoxicity and Superoxide Scavenging Activity
Letters in Drug Design & Discovery The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain
Current Neuropharmacology Telomere End Protection in Stem Cells and Cancer Cells
Current Cancer Therapy Reviews Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Probable Mechanisms Involved in Immunotoxin Mediated Capillary Leak Syndrome (CLS) and Recently Developed Countering Strategies
Current Molecular Medicine Probiotics as Biotherapeutic Agents: Present Knowledge and Future Prospects
Current Pharmaceutical Design